A federal court has ordered a Texas-based company to stop producing compounded drug products intended to be sterile until the company complies with the Federal Food, Drug, and Cosmetic Act and other requirements, the Food and Drug Administration announced today. The government alleges that Guardian Pharmacy Services distributed purportedly sterile drug products made under unsanitary conditions and in violation of current good manufacturing practice requirements. According to the complaint, the company also made and distributed misbranded drugs because their labels did not include adequate directions for patient use, were false or misleading. In 2017, the FDA received adverse event reports concerning at least 43 patients who received eye injections during cataract surgery of a drug compounded by Guardian.

Related News Articles

Perspective
Public
The 2025 AHA Leadership Summit wrapped up on July 22, and as always, it was energizing and inspiring to connect with so many talented and dedicated people…
Headline
The AHA July 24 announced it is collaborating with health care technology leader Epic to help hospitals adopt tools that support the early detection and…
Headline
Carolyn Bogard, DNP, R.N., director of care coordination and palliative care at El Camino Health, talks about her system’s use of data to harness the passion…
Headline
Hartford HealthCare in Hartford, Conn., will receive the 2025 AHA Quest for Quality Prize as a result of their sweeping transformation over the past decade —…
Headline
A Q&A in the July edition of AHA Trustee Insights features leaders from Winchester Hospital in Massachusetts discussing the importance of board members…
Headline
To help hospitals across the country improve sepsis care, the Centers for Disease Control and Prevention created the Hospital Sepsis Program Core Elements,…